Canavan disease: studies on the knockout mouse.

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Canavan disease (CD) is an inherited neurological disorder characterized by spongy degeneration of the brain.
• It stems from aspartoacylase (ASPA) deficiency, leading to N-acetylaspartic acid (NAA) accumulation in the brain and increased urinary NAA excretion.
• Clinical manifestations include macrocephaly, intellectual disability, and hypotonia.

Purpose of the Study:

• To investigate the molecular pathology of Canavan disease using a genetically engineered mouse model.
• To explore potential therapeutic strategies for Canavan disease.

Main Methods:

• Engineering a knockout mouse model exhibiting key features of Canavan disease, including ASPA deficiency and elevated NAA.
• Conducting molecular studies on the mouse brain to identify gene expression abnormalities.
• Applying adeno-associated virus-mediated gene transfer and stem cell therapy in the CD mouse model.

Main Results:

• The engineered mouse model accurately recapitulates Canavan disease phenotypes, including ASPA deficiency and elevated NAA.
• Molecular analysis revealed abnormal expression of multiple genes in the affected mouse brains, beyond just ASPA.
• Initial investigations into gene transfer and stem cell therapy showed promise in altering the disease's pathophysiology in the mouse model.

Conclusions:

• The Canavan disease mouse model serves as a valuable tool for studying disease mechanisms and testing therapeutic interventions.
• Gene transfer and stem cell therapy represent promising avenues for future Canavan disease treatments.
• Further research is warranted to fully elucidate the molecular pathways involved and optimize therapeutic approaches.